Dose a novel biomarker, RM2-Haptoglobin-beta, has the possibility to exceed PSA in predicting outcome of prostate cancer?

在我们之前的研究中，RM2定义的触珠蛋白- β链是一种新的血清标志物，当它与PSA或gan特异性标志物结合时，可能有助于早期前列腺癌的检测，因为它不是前列腺癌特异性的。在本研究中，我们试图建立检测前列腺癌患者血清中RM2定义的接触珠蛋白- β链的检测系统。触珠蛋白浓度与PSA无相关性。更重要的是，前列腺癌患者和良性前列腺疾病患者血清中接触珠蛋白的浓度没有差异。因此，有必要提高RM2定义的接触珠蛋白-链检测系统的质量。

In our previous study, haptoglobin-beta chain defined by RM2 is a novel serum marker that may be useful for detection of early prostate cancer when coupled with PSA as or gan-specific marker because it is not specific to prostate cancer. In current study, we tried to establish the assay system of detecting haptoglobin-beta chain defined by RM2 from sera of prostate cancer patients.There were no correlation between concentrations of haptoglobin and PSA. And more, there were no differences in concentrations of haptoglobin between sera of prostate cancer and sera of benign prostate disease. So it is necessary to improve the quality of detecting system of haptoglobin-beta chain defined by RM2.